Subscribe

Michael Singer, MD, PhD

Chief Scientific Officer, Cartesian Therapeutics

Articles by Michael Singer, MD, PhD

Michael Singer, MD, PhD

Combining RNA and CAR T-Cell Therapy for Myasthenia Gravis

ByMichael Singer, MD, PhD

March 23rd 2022

Michael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.

Michael Singer, MD, PhD

A Positive Outlook for Rare Disease Research: Michael Singer, MD, PhD

ByMichael Singer, MD, PhD

March 1st 2022

The cofounder and chief scientific officer of Cartesian Therapeutics discussed the importance of Rare Disease Day.

Michael Singer, MD, PhD

RNA-Modified vs DNA-Modified CAR T Products

ByMichael Singer, MD, PhD

September 10th 2021

Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.

Latest Updated Articles

A Positive Outlook for Rare Disease Research: Michael Singer, MD, PhD
Published: March 1st 2022 | Updated:

Trending on CGTlive®

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks

Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years

CGTLive®’s Weekly Rewind – October 17, 2025

© 2025 MJH Life Sciences^®

All rights reserved.